Abstract: The present application relates to methods of using compounds of Formulae (I) and (II): for treatment of various cancers. The application further relates to pharmaceutical compositions and uses comprising the compounds of the application.

Abstract: The present application relates to methods of using compounds of Formulae (I) and (II): for treatment of various cancers. The application further relates to pharmaceutical compositions and uses comprising the compounds of the application.

Abstract: Two isoforms of thyroid receptor alpha (THR?1 and THR?2) have been found to be associated with the growth of cancer. Use of inhibitors of THR?1 (Formula I) and/or agonists of THR?2 (Formula II) in the treatment of such cancers is disclosed. Treatment of other disorders associated with such receptors is also contemplated, as is the use of diagnostic methods for predicting therapeutic outcomes based on the levels of expression of THR?1 and THRa?2 in a tissue sample.

Abstract: Two isoforms of thyroid receptor alpha (THR?1 and THR?2) have been found to be associated with the growth of cancer. Use of inhibitors of THR?1 (Formula I) and/or agonists of THR?2 (Formula II) in the treatment of such cancers is disclosed. Treatment of other disorders associated with such receptors is also contemplated, as is the use of diagnostic methods for predicting therapeutic outcomes based on the levels of expression of THR?1 and THRa?2 in a tissue sample.

Abstract: A method of prognosis for a mammal with cancer is provided. The method includes the steps of determining in a biological sample obtained from the mammal the expression level of each biomarker of the group DSTN, TDRD3, RGS4, MYO1E, RPL3, Hypothetical FLJ13769, ANP32C, MC2R, DKFZp434L092, GPR27, HPS and LCP1; comparing the expression level of each biomarker with the expression level of a housekeeping gene; and rendering a prognosis for the mammal of a greater than 50% survival for an extended period of time when the expression level of DSTN, TDRD3, RGS4, MYO1E, RPL3(1), RPL3(2), RPL3(3), Hypothetical FLJ13769 and ANP32C is decreased in comparison to the expression of the housekeeping gene, and the expression level of MC2R, DKFZp434L092, GPR27, HPS5 and LCP1 is increased in comparison to the expression of the housekeeping gene.

Abstract: A method of enhancing the formation of extracellular matrix in culture. Cells in culture secrete most of the collagen into the media as unprocessed procollagen, i.e., the cells do not convert procollagen to collagen. In contrast, normal extracellular matrix deposition involves procollagen processing to collagen, fibril assembly and deposition into the cell layer to form a collagenous extracellular matrix. The addition of certain growth factors and the addition of a thin layer of a certain volume exclusion agent on top of the cells dramatically enhances the conversion of procollagen to collagen and will increase the amount of collagen and extracellular matrix associated with the cells. This invention advances bioengineering of connective tissues for medical applications that require an extensive and functional extracellular matrix with high tensile strength such as those in the cornea stroma, skin, tendons, ligaments, articular cartilage and the intervertebral disks.

Abstract: A method of enhancing the formation of extracellular matrix in culture. Cells in culture secrete most of the collagen into the media as unprocessed procollagen, i.e., the cells do not convert procollagen to collagen. In contrast, normal extracellular matrix deposition involves procollagen processing to collagen, fibril assembly and deposition into the cell layer to form a collagenous extracellular matrix. The addition of certain growth factors and the addition of a thin layer of a certain volume exclusion agent on top of the cells dramatically enhances the conversion of procollagen to collagen and will increase the amount of collagen and extracellular matrix associated with the cells. This invention advances bioengineering of connective tissues for medical applications that require an extensive and functional extracellular matrix with high tensile strength such as those in the cornea stroma, skin, tendons, ligaments, articular cartilage and the intervertebral disks.

Abstract: The invention provides a transgenic non-human animal expressing a perlecan encoding transgene. Also provided is a double-transgenic non-human animal expressing a perlecan and an amyloid encoding transgene. A method of screening for a compound which alters the rate or extent of amyloid deposition is additionally provided. The method consists of: (a) constructing a perlecan transgenic animal; (b) administering an effective amount of a test compound to said perlecan transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition. Finally, the invention provides a method of screening for a compound which alters the rate or extent of amyloid deposition. The method consists of: (a) constructing a perlecan/amyloid double-transgenic animal; (b) administering an effective amount of a test compound to said perlecan/amyloid double-transgenic animal; and (c) determining whether said test compound alters the extent o rate of amyloid deposition.

Abstract: The invention provides a transgenic non-human animal expressing a perlecan encoding transgene. Also provided is a double-transgenic non-human animal expressing a perlecan and an amyloid encoding transgene. A method of screening for a compound which alters the rate or extent of amyloid deposition is additionally provided. The method consists of: (a) constructing a perlecan transgenic animal; (b) administering an effective amount of a test compound to said perlecan transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition. Finally, the invention provides a method of screening for a compound which alters the rate or extent of amyloid deposition. The method consists of: (a) constructing a perlecan/amyloid double-transgenic animal; (b) administering an effective amount of a test compound to said perlecan/amyloid double-transgenic animal; and (c) determining whether said test compound alters the extent o rate of amyloid deposition.

Abstract: A long-range cattle identification system used to monitor a plurality of animals. The system uses a plurality of electronic information tags that are attachable to animals. The electronic information tags transmit and receive electronic information with at least one other electronic information tag. The electronic information tags are spatially disposed so that one electronic information tag can transmit and receive at least one other electronic information tag's individual electronic information to form a mesh network. The system includes a communication device that can communicate with at least one electronic information tag and receive information from that tag. The communication device can also receive the information contained in all the other electronic information tags in the mesh network through the at least one electronic information tag.

Abstract: The invention provides a transgenic non-human animal expressing a perlecan encoding transgene. Also provided is a double-transgenic non-human animal expressing a perlecan and an amyloid encoding transgene. A method of screening for a compound which alters the rate or extent of amyloid deposition is additionally provided. The method consists of: (a) constructing a perlecan transgenic animal; (b) administering an effective amount of a test compound to said perlecan transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition. Finally, the invention provides a method of screening for a compound which alters the rate or extent of amyloid deposition. The method consists of: (a) constructing a perlecan/amyloid double-transgenic animal; (b) administering an effective amount of a test compound to said perlecan/amyloid double-transgenic animal; and (c) determining whether said test compound alters the extent o rate of amyloid deposition.

Abstract: The invention provides a transgenic non-human animal expressing a perlecan encoding transgene. Also provided is a double-transgenic non-human animal expressing a perlecan and a amyloid encoding transgene. A method of screening for a compound which alters the rate or extent of amyloid deposition is additionally provided. The method consists of: (a) constructing a perlecan transgenic animal; (b) administering an effective amount of a test compound to said perlecan transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition. Finally, the invention provides a method of screening for a compound which alters the rate or extent of amyloid deposition. The method consists of: (a) constructing a perlecan/amyloid double-transgenic animal; (b) administering an effective amount of a test compound to said perlecan/amyloid double-transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition.